Evaluation of NT-proBNP in Chronic Inflammatory Bowel Disease

Not Applicable

Terminated

• Conditions: NT-pro-BNP; Inflammatory Bowel Diseases
• Interventions: Other: Evaluate the blood level of NTproBNP

• Registration Number: NCT03107390
• Lead Sponsor: Centre Hospitalier Universitaire, Amiens

Brief Summary

NT-proBNP is a major diagnostic and prognostic marker in cardiology, but it is also a new marker for biological inflammation, especially in rheumatology.

Its evaluation in chronic inflammatory bowel disease was carried out in a preliminary study, the OPERA study where in a population of 12 patients showed an increase in NT-proBNP correlated with the biological and endoscopic activity of the disease. This larger study is therefore a pilot study that could see NTproBNP as a new biomarker of inflammation in MICI.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-10-28
• Study First Submitted: 2017-04-05
• Study First Submitted QC: 2017-04-10
• Study First Posted: 2017-04-11
• Primary Completion: 2017-08-07
• Study Completion: 2017-08-07
• Status Verified: 2020-07
• Last Update Submitted: 2020-07-13
• Last Update Posted: 2020-07-15

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 159

Inclusion Criteria

• Adult subjects (age 18 years)
• MICI Group: Patients monitored for probable HC or MC
• Control group: Patients referred for consultation in gastroenterology with a clinical and endoscopic picture eading to the diagnosis of TF I
• Person who agreed to participate in the study
• Patient covered by social insurance

Exclusion Criteria

• Causes of increased concentrations of natriuretic peptides: acute heart failure, acute or chronic pulmonary disease with right ventricular repercussion, valvulopathies, primary or secondary HVG, atrial fibrillation cardiac arrhythmia, chronic systolic dysfunction, hyperthyroidism, Addison's disease, hyperaldosteronism Primary, diabetes, cirrhosis with ascites, cancers, chronic renal insufficiency.
• Inflammatory and autoimmune diseases (excluding MC and RCH), chronic inflammatory syndrome
• Ongoing treatment that may affect the concentration of natriuretic peptides: ACE inhibitor, angiotensin II receptor antagonists, diuretics
• Patient deprived of liberty or protected major (under guardianship or curatorship)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
The control population	Evaluate the blood level of NTproBNP	-
Patients with CD or RCH	Evaluate the blood level of NTproBNP	-

Primary Outcome Measures

Name	Time	Method
Blood level of NTproBNP.	1 month

Trial Locations

Locations (1)

CHU Amiens Picardie; 🇫🇷 Amiens, Picardie, France